

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Genscript Biotech Corporation

金斯瑞生物科技股份有限公司 *

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1548)

**OVERSEAS REGULATORY ANNOUNCEMENT
LEGEND BIOTECH ANNOUNCES NOTIFICATION OF DELINQUENCY FROM THE
NASDAQ STOCK MARKET LLC**

This announcement is made by the board of directors (the “**Board**”) of GenScript Biotech Corporation (the “**Company**”) pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

Legend Biotech Corporation (“**Legend Biotech**”), a non-wholly owned subsidiary of the Company, whose shares are listed by way of American Depositary Shares on the Nasdaq Global Select Market in the United States, has filed a Form 6-K with the United States Securities and Exchange Commission (the “**SEC**”) in relation to a notice (the “**Notice**”) issued to Legend Biotech by the Listing Qualifications Department of The Nasdaq Stock Market LLC (“**Nasdaq**”) on 6 January 2023 (New York time) indicating that Legend Biotech is not currently in compliance with the Listing Rules of Nasdaq (the “**Nasdaq’s Listing Rules**”) due to its failure to file an interim balance sheet and income statement as of and for the quarter ended 30 June 2022 on Form 6-K with the SEC (the “**Notification of Delinquency**”).

Pursuant to rule 5250(c)(2) of the Nasdaq’s Listing Rules, Legend Biotech was required to file such Form 6-K no later than six months following the end of the quarter ended 30 June 2022, or 31 December 2022 (the “**Due Date**”). As of the date of this announcement, Legend Biotech has not yet filed the required Form 6-K.

This delay in filing such Form 6-K has resulted from Legend Biotech’s planned restatement of its audited financial statements as of and for the years ended 31 December 2019, 31 December 2020 and 31 December 2021 and unaudited interim financial information for the three months ended 31 March 2022. Please refer to the Company’s announcement dated 21 October 2022 in relation to the proposed restatement of Legend Biotech’s financial statements for details.

The Notice has no immediate effect on the listing of Legend Biotech’s American Depositary Shares. Pursuant to the Notice, Legend Biotech has 60 days from the date of the Notice, or until 7 March 2023, to submit a proposal to regain compliance with the Nasdaq’s Listing Rules. If Nasdaq accepts Legend Biotech’s proposal, Nasdaq may grant Legend Biotech an extension of up to 180 calendar days from the Due Date, or until 29 June 2023, to regain compliance with the Nasdaq’s Listing Rules. Legend Biotech intends to fully comply with the time period afforded in the Notice and is actively working on its proposal to regain

compliance with the Nasdaq's Listing Rules.

The attachment is the full Form 6-K in relation to the Notification of Delinquency as published on the SEC's website available at <https://www.sec.gov/Archives/edgar/data/1801198/000115752323000031/0001157523-23-000031-index.htm>.

This announcement has been issued in the English language with a separate Chinese language translation. If there is any inconsistency or ambiguity between the English version and the Chinese version, the English version shall prevail.

Shareholders and potential investors of the Company are advised to pay attention to investment risks and exercise caution when they deal or contemplate dealing in the securities of the Company.

By order of the Board
Genscript Biotech Corporation
MENG Jiange
Chairman and Executive Director

Hong Kong, 9 January 2023

As at the date of this announcement, the executive Directors are Dr. Zhang Fangliang, Mr. Meng Jiange, Ms. Wang Ye and Dr. Zhu Li; the non-executive Directors are Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian, Mr. Pan Jiuan and Dr. Wang Xuehai.

** For identification purposes only*